<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: The objective is analyze the complementarity between 1H magnetic resonance spectroscopy (MRS) and magnetic resonance (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>) imaging in the global diagnosis of <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) or vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VD) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We studied 168 patients with <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> from AD, VD, mild <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> (MCI) and major <z:hpo ids='HP_0000716'>depression</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were evaluated by brain <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> imaging and MRS using two sample volumes localized at right medial temporal gyrus and posterior parietal gyrus </plain></SENT>
<SENT sid="3" pm="."><plain>Metabolites analyzed were N-acetylaspartate (<z:chebi fb="8" ids="32918">NAA</z:chebi>), <z:chebi fb="0" ids="17268">myo-Inositol</z:chebi> (mI), <z:chebi fb="3" ids="15354">Choline</z:chebi> (Cho) and <z:chebi fb="2" ids="16919">creatine</z:chebi> (Cr), as standard references for obtaining the Co/Cr, mI/Cr and <z:chebi fb="8" ids="32918">NAA</z:chebi>/Cr ratios </plain></SENT>
<SENT sid="4" pm="."><plain>Imaging and spectroscopy alterations were graded from 0 to 4 and the average of both was used to draw ROC and SROC curves </plain></SENT>
<SENT sid="5" pm="."><plain>Area under ROC curve (Az) was used as a measure of discriminative ability </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Combination of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> imaging and MRS significantly improved AD diagnosis (Global Az: 0.722 vs. <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> imaging Az: 0.624; p: 0.003) </plain></SENT>
<SENT sid="7" pm="."><plain>However, the combination of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> imaging and MRS did not improve VD diagnosis </plain></SENT>
<SENT sid="8" pm="."><plain>SROC curve obtained for the diagnosis of global <z:hpo ids='HP_0000726'>dementia</z:hpo> was Az: 0.6658 with 0.67 sensitivity and 0.65 specificity </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Combination of both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> techniques significantly improved AD diagnosis versus <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> imaging alone </plain></SENT>
<SENT sid="10" pm="."><plain>More studies are needed to enhance VD classification </plain></SENT>
<SENT sid="11" pm="."><plain>Metabolic data found by MRS can be useful to differentiate <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> </plain></SENT>
</text></document>